M. Schenk

发表

[Unclear liver lesions in a 19-year-old woman with acute myeloid leukemia].

J. Braess, C. Dierkes, B. Braun, 2016, Der Internist.

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).

V. Heinemann, T. Decker, C. Denzlinger, 2020, European journal of cancer.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Expression of Human Endogenous Retroviral (HERV) Sequences in Hematological Disorders

R. Hehlmann, M. Simon, W. Seifarth, 1996 .

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).

V. Heinemann, T. Decker, C. Denzlinger, 2022, European journal of cancer.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Fatal Liver Failure Associated with Valproate Therapy in a Patient with Friedreich's Disease: Review of Valproate Hepatotoxicity in Adults

R. Hehlmann, S. König, E. Holm, 1999, Epilepsia.

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

T. Zander, E. Maiello, R. Hofheinz, 2020 .

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

T. Brümmendorf, K. Spiekermann, M. Pfreundschuh, 2017, Leukemia.

Structural and Functional Features of the B-Cell Receptor in IgG-Positive Chronic Lymphocytic Leukemia

G. Packham, J. Orchard, F. Stevenson, 2006, Clinical Cancer Research.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

N. Reinmuth, A. Reuss, R. Penzel, 2015, European Respiratory Journal.

Lower frequency of allele loss on chromosome 18q in human breast cancer than in colorectal tumors

H. Saeger, S. Indraccolo, R. Hehlmann, 1996, Journal of Molecular Medicine.

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.

V. Heinemann, M. Lerch, K. Caca, 2018, European journal of cancer.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

J. Hasford, T. Brümmendorf, K. Spiekermann, 2018, Haematologica.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

M. Egger, V. Heinemann, J. Trojan, 2019, The Lancet.

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

F. Lordick, J. Trojan, U. Hacker, 2018, British Journal of Cancer.

Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

H. Heimpel, J. Hasford, M. Griesshammer, 2003, Leukemia.

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

R. Hofheinz, T. Gaiser, E. Goekkurt, 2021, Annals of Oncology.

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

V. Heinemann, T. Decker, C. Denzlinger, 2022, Frontiers in Oncology.

Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.

T. Zander, E. Maiello, R. Hofheinz, 2022, Journal of Clinical Oncology.

Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

M. Santis, W. Vervenne, W. Freier, 2014 .

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM

T. Zander, W. Bechstein, E. Maiello, 2023, International journal of cancer.

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

V. Heinemann, T. Decker, G. Schuch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

F. Lordick, J. Trojan, U. Hacker, 2018, British Journal of Cancer.

Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group.

R. Hehlmann, M. Simon, H. Kolb, 1994, Leukemia.

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial

T. Zhan, E. Goekkurt, J. Riera-Knorrenschild, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

A. Reuss, C. Kortsik, M. Eiff, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

R. Hofheinz, A. Wicki, S. Al-Batran, 2019, Journal of Clinical Oncology.

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis result

M. Staehler, M. Santis, W. Vervenne, 2012 .